Insider · CIK 0002046802
Daniel G. Baker
officerdirector
Files at CUE (Cue Biopharma, Inc.), ARTV (Artiva Biotherapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 8, 2026 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Jun 24, 2025 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Mar 21, 2025 | CUE Cue Biopharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Mar 25, 2025 |
| Jan 28, 2025 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +27,500 | $0.00 | $0 | 27,500 | Jan 29, 2025 |
| Nov 25, 2024 | CUE Cue Biopharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Nov 29, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.